4SA.F ACOUSORT AB O.N.

Healthcare Biotechnology Frankfurt Exchange
0.2430 EUR
Close of Nov 11, 2026
0.1240 0.4140
Market cap
EUR 5.14M
P/E
-
P/B
5.98x
ROE
-120.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 4SA.F undervalued?

Graham number

The Graham number of ACOUSORT AB O.N. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ACOUSORT AB O.N. fundamental analysis

No fundamental analysis for ACOUSORT AB O.N. yet.

ACOUSORT AB O.N. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ACOUSORT AB O.N.

AcouSort AB (publ), a technology company, develops components and instruments used in the diagnostics, analytics, and cell therapy processing markets. It offers AcouTrap, a benchtop research instrument for sample preparation of cells, extracellular vesicles, bacteria, and viruses from various media; AcouPlasma, a module that enables in-line analysis of blood plasma from whole blood samples; Acoustic Separation Module, a microfluidic solution that provides continuous separati…

Full company profile